On March 9th, Nanfang Finance News reported that Changfeng Pharmaceutical (02652.HK) issued a voluntary announcement stating that its Clinical Trial Application (CTA) for olopatadine-mometasone nasal spray has been approved by the National Medical Products Administration (NMPA) of the People's Republic of China. This product is the first olopatadine-mometasone nasal spray in China to submit a generic drug clinical trial application. It is intended for the treatment of moderate to severe allergic rhinitis symptoms in adults and adolescents aged 12 and above. It is a combination antihistamine and corticosteroid formulation, designed to improve treatment convenience and patient compliance. This approval marks the product's formal entry into the clinical trial stage and is an important validation of the company's capabilities in complex nasal spray formulations and drug-device integration technology. It also complements the existing AR/CRS product portfolio (such as Shufeimin® and mometasone furoate nasal spray), covering a wider age range and disease stage. The company will subsequently advance clinical research in accordance with regulatory requirements and continue to strengthen its innovative pipeline in the respiratory and nasal disease fields. It should be noted that drug development involves high risks and uncertainties, and CTA approval does not guarantee subsequent clinical success, market access, or commercialization.

https://finance.eastmoney.com/a/202603093665471271.html